TORONTO--(BUSINESS WIRE)--
Satellos Bioscience Inc.
(TSX:MSCL, OTCQB:MSCLF)
(“
Satellos
”
)
, a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, announced today that Frank Gleeson, Co-founder and CEO will participate in Oppenheimer’s Movers in Rare Disease Summit taking place in New York City on December 12, 2024.
Oppenheimer’s Movers in Rare Disease Summit
Title:
Polypharmacy in DMD and Neuromuscular Disease
Format:
Fireside Chat
Date:
December 12, 2024
Time:
9:50AM ET
Additionally, management will be available for one-on-one meetings with registered attendees at the summit.
About Satellos Bioscience Inc.
Satellos is a clinical-stage drug development company dedicated to developing life-improving medicines to treat degenerative muscle diseases. Satellos has invented SAT-3247 as a first-of-its-kind, orally administered small molecule drug designed to restore skeletal muscle regeneration initially in Duchenne muscular dystrophy (DMD). Satellos has generated a significant body of preclinical evidence in DMD to support that correcting muscle stem cell polarity with SAT-3247 has the potential to restore skeletal muscle regeneration to repair and strengthen muscle that has been damaged. The Company’s lead drug candidate SAT-3247 is currently in clinical development as a potential disease-modifying treatment DMD. Additionally, Satellos is leveraging its breakthrough research in muscle stem cell polarity and proprietary discovery platform MyoReGenX™, to identify degenerative muscle diseases where deficits in muscle regeneration occur that are amenable to therapeutic intervention for future clinical development. For more information, visit
www.satellos.com.
Source: Satellos Bioscience Inc.